The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Breakthrough Therapy status for rilzabrutinib in wAIHA addresses the lack of approved treatments for this rare and life-threatening condition.

HealthDay News — The US Food and Drug Administration (FDA) will now allow food labels to claim products have “no artificial colors” as long as they avoid petroleum-based dyes.

Fewer interval cancers that were invasive, T2+, or non-luminal A were found in group with AI-supported mammography versus standard double reading ...

Decrease in male-to-female ratio seen with increasing age at diagnosis and by calendar period for those aged older than 10 years ...

Another major medical group says most gender-related surgeries for minors in the US should be postponed until adulthood. The American Medical Association (AMA) said Wednesday that surgical ...

HealthDay News — For early-morning shift workers with shift work disorder (SWD), treatment with solriamfetol significantly improves sleepiness, according to a study published in the February issue of ...

Age-standardized prevalence varied by race and ethnicity group and by sex in 2022, with highest prevalence in non-Hispanic Black women.

HealthDay News — More than 31,000 nurses and health care workers walked off the job Monday morning at Kaiser Permanente ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

Amgen is providing prescribers with updated information regarding Tavneos (avacopan) following a request from the FDA to remove the product from the market.

HealthDay News — A fast-growing measles outbreak in South Carolina has eclipsed last year’s record-setting Texas surge. As of ...